ABBV Stock Recent News
ABBV LATEST HEADLINES
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Because dividend investing has such an impressive track record of beating non-dividend-paying stocks, many investors buy Dividend Aristocrats for their portfolios. It's not a bad strategy to begin with.
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareholder returns. Blending higher-yielding dividend stocks with those offering growth potential creates a balanced approach suitable for most investors.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
Blue-chip dividend stocks have always been relevant. While they're not the most exciting investments, they provide a steady hand during market uncertainty.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie has a handful of desirable features as an investment. It's also navigating a period of uncertainty successfully so far.
AbbVie is a profitability superstar with a strong track record of success, generating almost 40% in free cash flow margin. The company has a diverse portfolio of products across several promising drug markets, including an intact position in the immunology drugs market. The stock offers an attractive valuation, a solid dividend yield, and is recommended as a "Strong Buy" for long-term investors.